- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Aurora kinase targeting in lung cancer reduces KRAS-induced transformation ; volume:15 ; number:1 ; day:3 ; month:2 ; year:2016 ; pages:1-14 ; date:12.2016
Molecular cancer ; 15, Heft 1 (3.2.2016), 1-14, 12.2016
- Creator
-
dos Santos, Edmilson Ozorio
Carneiro-Lobo, Tatiana Correa
Aoki, Mateus Nobrega
Levantini, Elena
Bassères, Daniela Sanchez
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12943-016-0494-6
- URN
-
urn:nbn:de:101:1-2405122107087.532803252362
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- dos Santos, Edmilson Ozorio
- Carneiro-Lobo, Tatiana Correa
- Aoki, Mateus Nobrega
- Levantini, Elena
- Bassères, Daniela Sanchez
- SpringerLink (Online service)
Other Objects (12)
Correction: Aurora kinase targeting in lung cancer reduces KRAS-induced transformation
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy
Expressionsanalyse von Aurora-Kinase A, Aurora-Kinase B, Repp 86, Cyclin-Dependent-Kinase 1 und Cyclin-Dependent-Kinase 2 bei Mamma- und Ovarialkarzinomen
Expressionsanalyse von Aurora-Kinase A, Aurora-Kinase B, Repp 86, Cyclin-Dependent-Kinase 1 und Cyclin-Dependent-Kinase 2 bei Mamma- und Ovarialkarzinomen
Targeting mutant KRAS in pancreatic cancer: futile or promising?
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment
Aurora kinase inhibitors: Progress towards the clinic
Editorial: Targeting bruton tyrosine kinase
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models
Targeting neoepitopes derived from KRAS mutations for cancer-specific immunotherapy
Correction: Aurora kinase targeting in lung cancer reduces KRAS-induced transformation
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy
Expressionsanalyse von Aurora-Kinase A, Aurora-Kinase B, Repp 86, Cyclin-Dependent-Kinase 1 und Cyclin-Dependent-Kinase 2 bei Mamma- und Ovarialkarzinomen
Expressionsanalyse von Aurora-Kinase A, Aurora-Kinase B, Repp 86, Cyclin-Dependent-Kinase 1 und Cyclin-Dependent-Kinase 2 bei Mamma- und Ovarialkarzinomen
Targeting mutant KRAS in pancreatic cancer: futile or promising?
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment
Aurora kinase inhibitors: Progress towards the clinic
Editorial: Targeting bruton tyrosine kinase
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models
Targeting neoepitopes derived from KRAS mutations for cancer-specific immunotherapy
Correction: Aurora kinase targeting in lung cancer reduces KRAS-induced transformation
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy
Expressionsanalyse von Aurora-Kinase A, Aurora-Kinase B, Repp 86, Cyclin-Dependent-Kinase 1 und Cyclin-Dependent-Kinase 2 bei Mamma- und Ovarialkarzinomen
Expressionsanalyse von Aurora-Kinase A, Aurora-Kinase B, Repp 86, Cyclin-Dependent-Kinase 1 und Cyclin-Dependent-Kinase 2 bei Mamma- und Ovarialkarzinomen
Targeting mutant KRAS in pancreatic cancer: futile or promising?
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment
Aurora kinase inhibitors: Progress towards the clinic
Editorial: Targeting bruton tyrosine kinase
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models